The European Cardiac Surgery market, which is expected to reach a market value of €3.7 billion by 2030, is a dynamic landscape with several key players vying for dominance. In 2023, the market saw Edwards Lifesciences emerge as the top market share leader, followed closely by Abbott and Medtronic. In this blog, we delve into the strengths and strategies of these industry giants, focusing on Edwards Lifesciences and its remarkable performance in the tissue heart valve, annuloplasty repair, TMVr, and THVI device segments.
1. Edwards Lifesciences
Founded in 1958, Miles “Lowell” Edwards established Edwards Lifesciences with the intention of building the first artificial heart. Edwards Lifesciences is now one of the global leaders in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Edwards Lifesciences demonstrated an impressive stronghold in the European cardiac surgery device market, securing the top spot in tissue heart valves, annuloplasty repair devices, and THVI devices. The company’s expertise in these segments contributed to its overall leadership, although it faced competition in the TMVr devices category.
A significant portion of Edwards Lifesciences’ revenue stemmed from the THVI device segment, showcasing the success of its SAPIEN 3®, SAPIEN XT®, and CENTERA® devices. This accomplishment solidifies Edwards Lifesciences’ position as a key player in the European market, leveraging its innovation and product excellence.
Abbott, the second-leading competitor, made strategic moves to enhance its market presence. The acquisition of St. Jude Medical played a pivotal role in Abbott’s ascent, cementing its position in various device segments, including tissue heart valves, mechanical heart valves, annuloplasty repair devices, TMVr, TAVI, VAD, PFO, LAA, ASD, and VSD.
The MitraClip® TMVr system, a standout offering from Abbott, contributed significantly to the company’s market share within the TMVr segment. The synergy created through strategic acquisitions and product excellence propelled Abbott to a leading position in the European cardiac surgery market.
Medtronic, the third-leading competitor, showcased a diverse portfolio spanning tissue heart valves, mechanical heart valves, annuloplasty repair, THVI, ONCAB, OPCAB, autotransfusion, VAD, and preshaped guidewires. Despite trailing behind Abbott and Edwards Lifesciences, Medtronic remained a formidable force in the market.
One of Medtronic’s notable achievements was its significant presence in the TAVI market. The Conformité Européene (CE) mark approval for the Evolut™ TAVI system in low-risk patients marked a strategic milestone, potentially enabling Medtronic to regain market share. The company’s wide-ranging product offerings and global dominance position it as a major competitor in the cardiac surgery device market.
The European cardiac surgery market is witnessing intense competition among the top 3 market share leaders. Edwards Lifesciences, Abbott, and Medtronic have established themselves as key players, each contributing unique strengths to the industry. As technological advancements continue to shape the landscape, these companies are poised to further elevate their positions and drive innovation in the evolving field of cardiac surgery devices.
To learn more about these three companies, along with the other companies competing within this market, visit our product page through the link or request a complimentary executive summary of the report below.